Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2003 1
2004 1
2005 1
2006 1
2008 2
2009 2
2010 1
2011 3
2012 2
2013 4
2014 9
2015 15
2016 24
2017 20
2018 24
2019 22
2020 24
2021 18
2022 25
2023 26
2024 26
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Results by year

Filters applied: . Clear all
Page 1
Nanomaterial-Based CO2 Sensors.
Rezk MY, Sharma J, Gartia MR. Rezk MY, et al. Nanomaterials (Basel). 2020 Nov 13;10(11):2251. doi: 10.3390/nano10112251. Nanomaterials (Basel). 2020. PMID: 33202957 Free PMC article. Review.
Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial.
Leng X, Leszczyński P, Jeka S, Liu SY, Liu H, Miakisz M, Gu J, Kilasonia L, Stanislavchuk M, Yang X, Zhou Y, Dong Q, Rezk M, Mitroiu M, Addison J, Zeng X. Leng X, et al. Among authors: rezk m. Lancet Rheumatol. 2024 Jan;6(1):e40-e50. doi: 10.1016/S2665-9913(23)00237-0. Lancet Rheumatol. 2024. PMID: 38258678 Clinical Trial.
A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48).
Leng X, Leszczyński P, Jeka S, Liu S, Liu H, Miakisz M, Gu J, Kilasonia L, Stanislavchuk M, Yang X, Zhou Y, Dong Q, Mitroiu M, Addison J, Rezk MF, Zeng X. Leng X, et al. Among authors: rezk mf. Arthritis Res Ther. 2024 Sep 7;26(1):157. doi: 10.1186/s13075-024-03375-w. Arthritis Res Ther. 2024. PMID: 39244595 Free PMC article. Clinical Trial.
Motor-neuron-disease-like phenotype associated with IgLON5 disease.
Sista SR, Crum B, Aboseif A, Devine MF, Zekeridou A, Hammami MB, Rezk MM, Truffert A, Lalive PH, Kunchok A, McKeon A, Dubey D. Sista SR, et al. Among authors: rezk mm. J Neurol. 2022 Nov;269(11):6139-6144. doi: 10.1007/s00415-022-11262-0. Epub 2022 Jul 20. J Neurol. 2022. PMID: 35857139 Free PMC article.
212 results